尊龙凯时·(中国)人生就是搏!
ABOUT US
NEWS
INVESTOR RELATIONS
簡
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
簡
繁
EN
簡
繁
EN
COMPANY NEWS
Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance
2024.03.19
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024.03.18
Change of Address of Head Office and Principal Place of Business in Hong Kong
2024.01.03
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2023-04-11
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China
2023-03-08
Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance
2023-03-08
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023-02-23
2023-02-22
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
2023-02-10
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
2022-10-13
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech
2022-08-24
Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance
<
1
2
3
4
5
6
7
...
9
>
Essex-Bio Group
BIOTECH
HEALTHTECH
Links
Wuhan Adv.Dental Bio-Technology
UNO Medical Group
Antikor Biopharma
Mitotech S.A.
Henlius
Humacyte
Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer
|
Privacy Policy
粵公網安備 44049102496184號粵ICP備09032349號-1
互聯網藥品信息服務資格證書編號:(粵)-非經營性-2024-0208
深圳網站建設 深圳聯雅
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
ACCEPT